Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
29 hedge funds and large institutions have $1.55M invested in Seelos Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
9% less funds holding
Funds holding: 32 → 29 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
40% less capital invested
Capital invested by funds: $2.58M → $1.55M (-$1.03M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GJL
Gendell Jeffrey L
|
+$327K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$290K |
| 3 |
WE
Wealth Effects
Boston,
Massachusetts
|
+$245K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$118K |
| 5 |
MWM
Modera Wealth Management
Westwood,
New Jersey
|
+$90.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$422K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$56.3K |
| 3 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$55.6K |
| 4 |
Morgan Stanley
New York
|
-$14.6K |
| 5 |
Two Sigma Investments
New York
|
-$12.5K |
SEEL Hedge Fund Activity: Q1 2024 in Review
29 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2024, worth a combined $1.55M — down 40% from $2.58M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SEEL and 5 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 10 added.
The largest buyer was Gendell Jeffrey L, adding an estimated $327K. The largest seller was Mirae Asset Global Investments, exiting entirely with an estimated $422K sold.
- 29 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2024, down from 32 in Q4 2023.
- Funds reported $1.55M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2024, down 40% quarter-over-quarter.
- 5 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2024 and 8 closed out, a net change of -3 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2024 was Gendell Jeffrey L, an estimated $327K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2024 was Mirae Asset Global Investments, an estimated $422K sold.
Based on aggregated 13F filings for Q1 2024.